ALLMedicine™ Urticarial Vasculitis Center
Research & Reviews 102 results
Dermatologic Therapy; Mansouri P, Mozafari N et. al.
Oct 14th, 2022 - The treatment of chronic urticaria (CU) is difficult, currently, antihistamines (AH) are the mainstay of treatment, however, up to 40% of patients do not respond to even high (four-fold) daily doses of AH. Tofacitinib is, a small-molecule that blo...
Rheumatology (Oxford, England); Breillat P, Jachiet M et. al.
Oct 4th, 2022 - To describe the clinical and pathological features of biopsy-proven cutaneous vasculitis (CV) associated with systemic lupus erythematosus (SLE), focusing on diagnosis classification and impact on overall SLE activity. Retrospective multicentric c...
Journal of Medical Case Reports; Smets K, Van Baelen A et. al.
Aug 22nd, 2022 - Urticarial vasculitis is a clinicopathologic entity defined by recurrent episodes of urticarial lesions that persist > 24 hours and demonstrate the histopathologic features of leukocytoclastic vasculitis. The most important prognostic feature is t...
Clinics in Dermatology; Magro CM, Mo JH et. al.
Jul 31st, 2022 - Cutaneous leukocytoclastic vasculitis (LCV) has a distinctive clinical and light microscopic presentation; however, the etiologic basis of LCV is varied. Most cases are attributable to immune complex deposition within a vessel wall and represent a...
Journal of Clinical Immunology; Tusseau M, Lovšin E et. al.
Jun 8th, 2022 - Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated with a lupus phenotype. It is unclear whether...
Clinicaltrials.gov 2 results
May 20th, 2021 - Backgrounds: Urticaria is a common disorder that present with localized edema reaction caused by dilatation and increased permeability of small blood vessels in skin and mucosa. The main clinical manifestations are wheal and erythema reaction. Chr...
May 31st, 2012 - This is a single-center open label study to assess the efficacy and safety of single doses of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody that neutralizes IL-1β, in patients with active urticarial vasculitis. Efficacy is ...
News 8 results
Aylin Türel Ermertcan, MD, Ayşe Aktaş, MD et. al.
Jun 2nd, 2021 - To the Editor: Urticarial vasculitis (UV) is a clinicopathologic entity. It manifests as an eruption of erythematous wheals that clinically resemble urticaria, but the lesions of UV last longer, may leave residual hyperpigmentation, and may or may.
Mar 27th, 2018 - Cutaneous biopsy findings from urticaria lesions may be divided into the following categories, because the response to treatment may be different: Class 1: A mixture of perivascular dermal inflammatory infiltrates composed of lymphocytes, monocyte...
May 1st, 2015 - ASHEVILLE, N. C.
Nov 29th, 2014 - Hypocomplementemic urticarial vasculitis (HUV) is an uncommon systemic vasculitis with various clinical manifestations for which an optimal therapeutic strategy has yet to be defined, a report from the French Vasculitis Study Group indicates. A Fr...
Feb 6th, 2013 - Hello. I am Jonathan Kay, Professor of Medicine and Director of Clinical Research in the Division of Rheumatology at the University of Massachusetts Medical School and UMass Memorial Medical Center, both in Worcester, Massachusetts. Today I would ...